Lia K Rosenstein
Overview
Explore the profile of Lia K Rosenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kivity Y, Levy K, Johnson B, Rosenstein L, LeBreton J
Clin Psychol Rev
. 2024 Feb;
108:102395.
PMID: 38320421
Background: Mentalizing, making sense of mental states, is hypothesized to have a central role in self-organization and social learning. Findings support this notion, but the extent of the association between...
2.
Bliton C, Rosenstein L, Pincus A
Front Psychol
. 2022 Mar;
13:794624.
PMID: 35237208
The - Alternative Model for Personality Disorders (AMPD) dimensionally defines personality pathology using severity of dysfunction and maladaptive style. As the empirical literature on the clinical utility of the AMPD...
3.
Ellison W, Rosenstein L, Morgan T, Zimmerman M
Psychiatr Clin North Am
. 2018 Nov;
41(4):561-573.
PMID: 30447724
Several studies of the prevalence of borderline personality disorder in community and clinical settings have been carried out to date. Although results vary according to sampling method and assessment method,...
4.
Rosenstein L, Ellison W, Walsh E, Chelminski I, Dalrymple K, Zimmerman M
Personal Disord
. 2018 Aug;
9(6):590-594.
PMID: 30091618
In the present report from the Rhode Island Methods to Improve Diagnostic Assessment and Services project, we examined the role of emotion dysregulation as a mediator between childhood abuse and...
5.
Zimmerman M, Multach M, Clark H, Walsh E, Rosenstein L, Gazarian D
Int J Geriatr Psychiatry
. 2016 Aug;
32(9):1009-1016.
PMID: 27546477
Objective: The generalizability of antidepressant efficacy trials (AETs) has been questioned. No studies have examined the inclusion/exclusion criteria used in placebo-controlled studies of late life depression and compared them to...
6.
Zimmerman M, Guzman Holst C, Clark H, Multach M, Walsh E, Rosenstein L, et al.
CNS Drugs
. 2016 Aug;
30(12):1209-1218.
PMID: 27541608
Background: Concerns about the generalizability of pharmacotherapy efficacy trials to "real-world" patients have been raised for more than 40 years. Almost all of this literature has focused on treatment studies...
7.
Zimmerman M, Clark H, Multach M, Walsh E, Rosenstein L, Gazarian D
J Affect Disord
. 2016 Mar;
198:39-42.
PMID: 27002283
Background: Substance use disorders are the most commonly excluded psychiatric disorder in antidepressant efficacy trials (AETs). In a recent review of AETs we noticed variability in the definition of the...
8.
Zimmerman M, Clark H, Multach M, Walsh E, Rosenstein L, Gazarian D
J Clin Psychopharmacol
. 2016 Feb;
36(2):153-6.
PMID: 26848791
The most commonly used inclusion/exclusion criterion in antidepressant efficacy trials (AETs) is a minimum score on a symptom severity scale. In the present study, we reviewed placebo-controlled AETs published during...
9.
Zimmerman M, Multach M, Walsh E, Rosenstein L, Gazarian D, Clark H
CNS Drugs
. 2016 Jan;
30(3):185-91.
PMID: 26818632
We recently conducted a comprehensive review of the psychiatric inclusion and exclusion criteria used in 170 placebo-controlled antidepressant efficacy trials (AETs) that were published between 1995 and 2014. In conducting...
10.
Zimmerman M, Clark H, Multach M, Walsh E, Rosenstein L, Gazarian D
J Affect Disord
. 2015 Nov;
190:357-361.
PMID: 26546771
Background: We recently conducted a comprehensive review of the psychiatric inclusion/exclusion criteria used in 170 placebo-controlled antidepressant efficacy trials (AETs) published during the past 20 years and found that the...